3DRT辅助卡培他滨与奥沙利铂化疗方案对进展期胃癌术后生存研究

doi:10.3760/cma.j.issn.1004-4221.2018.07.007

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的探讨三维适形调强放疗联合奥沙利铂+卡培他滨化疗治疗进展期胃癌对其术后中位生存时间的影响。方法自临沂市中心医院2010年2月至2012年1月选取进展期胃癌患者中选取74例,根据治疗方案分为术后化疗组(37例)与术后放化疗组(37例)。两组均采用腹腔镜D2根治术,术后化疗组采用奥沙利铂联合卡培他滨化疗,术后放化疗组采用奥沙利铂联合卡培他滨化疗+三维适形调强放疗,两组均化疗4个周期。疗程结束后统计对比两组不良反应发生情况、中位无进展生存时间、中位生存时间、治疗后1、3、5年疾病复发率及病死率。结果术后放化疗组骨髓抑制率(41%)、肝功能异常率(30%)、呕吐恶心率(30%)、白细胞减少率(46%)与术后化疗组(35%、35%、24%、41%)相比,差异无统计学意义(P>0.05)。术后放化疗组中位无进展生存时间、中位生存时间较术后化疗组长,差异有统计学意义(P<0.05)。两组治疗后1、3、5年疾病复发率比较,术后放化疗组(8%、14%、16%)较术后化疗组(32%、41%、46%)低,差异有统计学意义(P<0.05);术后放化疗组病死率11%(4/37)较术后化疗组30%(11/37)低,差异有统计学意义(P<0.05)。结论三维适形调强放疗联合奥沙利铂+卡培他滨化疗治疗进展期胃癌,可有效延长患者中位生存时间,降低疾病复发率,且不会增加不良反应发生风险。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张培良
	张焕珍
	张丹丹

关键词 ：胃肿瘤/三维放射疗法, 胃肿瘤/化学疗法, 预后

Abstract：

Objective To investigate the effect of three-dimensional conformal intensity-modulated radiotherapy combined with oxaliplatin plus capecitabine chemotherapy upon the postoperative median survival time of patients diagnosed with advanced gastric cancer. Methods A total of 74 patients with advanced gastric cancer admitted to Linyi Central Hospital from February 2010 to January 2012 were recruited and divided into the postoperative chemotherapy group (n=37) and postoperative radiotherapy and chemotherapy group (n=37) according to the treatment plan. All patients in two groups were treated with laparoscopic D2 radical operation. In the postoperative chemotherapy group, patients were treated with oxaliplatin combined with capecitabine. In the postoperative radiotherapy and chemotherapy group, patients were treated with oxaliplatin combined with capecitabine plus three-dimensional conformal radiotherapy. In both groups, 4 cycles of chemotherapy were delivered. The incidence of adverse reactions, median progression-free survival, median overall survival, and 1-, 3-and 5-year recurrence rate and mortality rate were statistically compared between two groups. Results In the postoperative radiotherapy and chemotherapy group, the incidence rate of bone marrow suppression (41%), abnormal liver function (30%), nausea and vomiting (30%) and neutropenia (46%) did not significantly differ from 35%, 35%, 24% and 41% in the postoperative chemotherapy group (all P>0.05).In the postoperative radiotherapy and chemotherapy group, the median progression-free survival and median overall survival were significantly longer compared with those in the postoperative chemotherapy group (both P<0.05).The 1-, 3-and 5-year recurrence rates were 8%, 14% and 16% in the postoperative radiotherapy and chemotherapy group, significantly lower than 32%, 41% and 46% in the postoperative chemotherapy group (all P<0.05).The mortality rate was 11%(4/37) in the postoperative radiotherapy and chemotherapy group, which was significantly lower than 30%(11/37) in the postoperative chemotherapy group (P<0.05). Conclusions Three-dimensional conformal radiotherapy combined with oxaliplatin plus capecitabine chemotherapy can effectively prolong the median survival, reduce the recurrence rate and does not enhance the risk of adverse events for patients with advanced gastric cancer.

Key words： Gastric neoplasms/three-dimensional radiotherapy Gastric neoplasms/chemotherapy Prognosis

收稿日期: 2017-11-27

引用本文:

张培良,张焕珍,张丹丹. 3DRT辅助卡培他滨与奥沙利铂化疗方案对进展期胃癌术后生存研究[J]. 中华放射肿瘤学杂志, 2018, 27(7): 661-664.

Zhang Peiliang,Zhang Huanzhen,Zhang Dandan. Effect of three-dimensional conformal intensity-modulated radiotherapy combined with capecitabine and oxaliplatin chemotherapy on postoperative survival in patients with advanced gastric cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(7): 661-664.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.07.007 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I7/661

[1] Bang Y,Kim Y W,Yang H,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer:Results of the phase Ⅲ CLASSIC trial[J].　Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2011,29(15):4002.
[2] 张雪刚,柯贤胜.　卡培他滨联合奥沙利铂治疗进展期老年胃癌患者的疗效和安全性[J].实用临床医药杂志,2014,18(11):109-110.　DOI:10.7619/jcmp.201411038.
Zhang XG,Ke XS.Efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer in elderly patients[J].Practical Journal of clinical medicine,2014,18(11):109-110.DOI:10.7619/jcmp.201411038.
[3] Xiang X J,Zhang L,Qiu F,et al. A phase Ⅱ study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer[J].Chemotherapy,2012,58(1):1-7.DOI:10.1159/ 000335585.
[4] 马保庆.两种化疗方案对老年晚期胃癌患者疗效比较[J].中国老年学杂志,2015,35(10):2729-2731.DOI:10.3969/j.issn.1005-9202.2015.10.064.
Ma BQ.Comparison of two chemotherapy regimens in elderly patients with advanced gastric cancer[J].Chinese Journal of Gerontology,2015,35(10):2729-2731.DOI:10.3969/j.issn.1005-9202.2015.10.064.
[5] Kim G M,Jeung H C,Sun Y R,et al. A randomized phase Ⅱ trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer[J].European Journal of Cancer,2012,48(4):518-526.DOI:10.1016/j.ejca.2011.12.017.
[6] 姬颖华,杨晓煜,陈美玲,等.XELOX方案与SOX方案治疗老年Ⅳ期肠型胃癌疗效对比[J].中国老年学杂志,2015,35(10):2723-2724.DOI:10.3969/j.issn.1005-9202.2015.10.060.
[7] Liu G F,Bair R J,Bair E,et al. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy[J].Plos One,2014,9(1):82642.DOI:10.1371/journal.pone.0082642.
[8] 陈孝平,汪建平.外科学[M].第8版.北京:人民卫生出版社,2013:360-364.
Chen XP,Wang JP.Surgery[M].Eighth Edition. Beijing:People′s Medical Publishing House, 2013:360-364.
[9] Adas YG,Andrieu MN,Hicsonmez A,et al. Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy[J].Asian Pacific Journal of Cancer Prevention Apjcp,2014,15(17):7401.
[10] 余嘉文,郝吉庆,胡智刚,等.局部进展期胃癌D2根治术后同步放化疗与单纯化疗的疗效比较[J].第二军医大学学报,2016,37(2):177-183.DOI:10.16781/j.0258-879x.2016.02.0177.
[11] Morganti A G,Di C A,Massaccesi M,et al. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer:a systematic review[J].British Journal of Radiology,2013,86(1029):508-520.DOI:10.1259/bjr.20130274.
[12] Leong T,Joon D L,Willis D,et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil:a multicenter study of the Trans-Tasman Radiation Oncology Group[J].International Journal of Radiation Oncology Biology Physics,2011,79(3):690-695.DOI:10.1016/j.ijrobp.2009.11.042.
[13] Wydmanski J,Grabinska K,Polanowski P,et al. Radiotherapy and chemoradiotherapy as a novel option for the treatment of locally advanced inoperable gastric adenocarcinoma:A phase Ⅱ study[J].Mol Clin Oncol,2014,2(2):1150-1154.DOI:10.3892/mco.2014.348
[14] 徐伟,吴福林,孙春花.卡培他滨联合奥沙利铂治疗进展期胃癌老年患者的疗效观察[J].实用癌症杂志,2014,29(12):1604-1606.DOI:10.3969/j.issn.1001-5930.2014.12.030.
[15] Dong C X,Fu J F,Ye X Y,et al. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy[J].World Journal of Gastroenterology,2014,20(34):12355.DOI:10.3748/wjg.v20.i34.12355.
[16] 刘丽霞,李国平,孙刚庆.胃癌术后三维适形放疗同步XELOX方案治疗的临床疗效[J].江苏医药,2014,40(13):1536-1538.
[17] 刘广国,肖仕明,赵清梅,等.局部进展期胃癌根治术后三维适形放疗联合同期化疗与单纯化疗的对比研究[J].现代中西医结合杂志,2015,24(30):3321-3323.DOI:10.3969/ j.issn.1008-8849.2015.30.005.
[18] 姚春梅,肖克源,马淑盟,等.进展期胃癌术后辅助放化疗与单纯化疗的比较[J].重庆医学,2016,45(17):2348-2351.
[19] 陶新节,杨林,陈象逊,等.局部进展期胃癌术后放化疗与单纯化疗疗效观察[J].中华肿瘤防治杂志,2015,22(18):1484-1487.
[20] Shulman K,Haim N,Wollner M,et al. Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin:A feasibility study[J].Oncol Letters,2012,3(5):1154.DOI:10.3892/ol.2012.617.
[21] Minn A Y,Hsu A,Trang La M D,et al. Comparison of intensity- modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer[J].Cancer,2010,116(16):3943.DOI:10.1002/cncr.25246.